CHCT · Community Healthcare Trust Inc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| % Leased | 89.8% | 2Q 2026 | — |
|
|
|||
| Adjusted EBITDAre non-GAAP | $23.25M | 2Q 2026 | — |
GAAP → non-GAAP reconciliationGAAP EBITDAre 20.47M
+2.78M Non-cash stock-based compensation expense
+0K Accelerated amortization of stock-based compensation
+0K Credit loss reserve
= Adjusted EBITDAre 23.25M
|
|||
| Adjusted EBITDAre Annualized non-GAAP | $93M | 2Q 2026 | — |
| Adjusted funds from operations (AFFO) non-GAAP | $15.41M | Three Months Ended June 30, 2026 | — |
| Adjusted funds from operations (AFFO) per diluted common share non-GAAP | $0.56 | Three Months Ended June 30, 2026 | — |
|
|
|||
| AFFO Payout non-GAAP | 87% | Q2 2026 | — |
| AFFO, Adjusted for other non-cash items non-GAAP | $15.64M | 2Q 2026 | — |
GAAP → non-GAAP reconciliationGAAP AFFO 15.41M
+24K Non-real estate depreciation and amortization
-41K Amortization of above (below) market leases
+255K Amortization of debt issuance costs
= AFFO, Adjusted for other non-cash items 15.64M
|
|||
| Annualized NOI non-GAAP | $101.44M | 2Q 2026 | — |
| Common shares outstanding | 28,654,743 | 2Q 2026 | — |
|
|
|||
| Debt/Total Capitalization | 43.9% | Q2 2026 | — |
|
|
|||
| Dividend yield | 7.2% | Q2 2026 | — |
|
|
|||
| EBITDAre non-GAAP | $20.47M | 2Q 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net income (loss) 2.36M
+7.43M Interest expense
+10.74M Depreciation and amortization
-12K Deferred Income tax (benefit) expense
-46K (Gain) loss, net of impairment, on the sale of real estate assets
= EBITDAre 20.47M
|
|||
| FAD non-GAAP | $12.99M | 2Q 2026 | — |
GAAP → non-GAAP reconciliationGAAP AFFO, Adjusted for other non-cash items 15.64M
-202K Leasing commissions
-1.11M Tenant improvements
-1.34M Recurring capex
= FAD 12.99M
|
|||
| FFO per Common Share non-GAAP | $0.48 | 2Q 2026 | — |
| Fixed charge coverage ratio | 3 | 2Q 2026 | — |
| Funds from operations (FFO) non-GAAP | $13.22M | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net Income (Loss) 2.36M
+10.9M Real estate depreciation and amortization
+0K Credit loss reserve
-46K (Gain) loss, net of impairment, on the sale of real estate assets
= FFO 13.22M
|
|||
| Funds from operations (FFO) per diluted common share non-GAAP | $0.48 | Three Months Ended June 30, 2026 | — |
|
|
|||
| Gross real estate investments | 1.25B | 2Q 2026 | — |
|
|
|||
| investments in real estate properties | 1.2B | As of June 30, 2026 | — |
| Leased Occupancy | 89.8% | 2Q 2026 | — |
| Leverage ratio | 44.6% | 2Q 2026 | — |
| Minimum debt service coverage ratio | 3.2 | 2Q 2026 | — |
| NOI non-GAAP | $25.36M | 2Q 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net income (loss) 2.36M
+4.89M General and administrative
+0K Accelerated amortization of deferred compensation
+0K Severance and transition-related compensation
+10.74M Depreciation and amortization
-46K (Gain) loss, net of impairment, on the sale of real estate assets
+0K Credit loss reserve
+7.43M Interest expense
-12K Deferred Income tax (benefit) expense
-3K Interest and other income, net
= NOI 25.36M
|
|||
| Portfolio Leased | 89.8% | Q2 2026 | — |
| Portfolio Occupancy | 89.8% | Q2 2026 | — |
| real estate properties | 197 | As of June 30, 2026 | — |
|
|
|||
| states with properties | 36 | As of June 30, 2026 | — |
| Tangible net worth | 695.59M | 2Q 2026 | — |
| Tenants | 325 | Q2 2026 | — |
| total square feet of properties | 4.5M | As of June 30, 2026 | — |
| Total square feet owned | 4,520,097 | 2Q 2026 | — |
|
|
|||
| Weighted Average Lease Term | 7.2 | Q2 2026 | — |
| Weighted Average remaining lease term | 7.2 | 2Q 2026 | — |
| Equity market cap | $467.5M | Q4 2025 | — |
| Quarter end stock price (per share) | $16.42 | Q4 2025 | — |
| Weighted average interest rate per annum on Revolving Line of Credit | 5.2% | Q4 2025 | — |
| Weighted average interest rate per annum on Term Loans | 4.7% | Q4 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
REIT - Healthcare Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CHCT
this stock
Community Healthcare Trust Inc
|
$426.08M | -9.4% | +4.7% | 21.9 | 3.5% |
|
WELL
Welltower Inc.
|
$167.58B | +27.9% | +35.6% | 118.1 | 2.5% |
|
VTR
Ventas, Inc.
|
$47.54B | +19.8% | +18.5% | 171.6 | 4.6% |
|
DOC
Healthpeak Properties, Inc.
|
$14.62B | +31.8% | +4.5% | 60.6 | 3.5% |
|
OHI
Omega Healthcare Investors Inc
|
$14.12B | +5.4% | +13.2% | 16.6 | 4.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CHCT | -1.7% | -18.9% | -12.6% | -18.8% | -9.4% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +0.3% | -22.2% | -23.8% | -20.9% | -21.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.